Rapid diagnostic tests (RDTs) are critical for preparedness and response against an outbreak or pandemic and have been highlighted in the 100 Days Mission, a global initiative that aims to prepare the ...

a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, today announced a strategic, worldwide partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime ...

The collaboration is set to develop a kit-based version of Foresight’s CLARITY™ assay, aiming to facilitate in vitro diagnostic (IVD) and companion diagnostic (CDx) applications for lymphoma and other ...

Together, the companies aim to lay the groundwork for a standardized, regulated diagnostic kit that, once validated and approved in pharmaceutical-sponsored trials, would be the only circulating ...

The collaboration is set to develop a kit-based version of Foresight’s CLARITY™ assay, aiming to facilitate in vitro diagnostic (IVD) and companion diagnostic (CDx) applications for lymphoma ...

NEW YORK – Qiagen and Foresight Diagnostics will codevelop a next-generation sequencing-based minimal residual disease companion diagnostic kit for lymphomas and other malignancies, the firms ...

A number of countries have solicited advisory reports on the state of governmental oversight and the affect of intellectual property issues concerning genetic testing. These reports were prepared ...

The National President of the Association of Medical Laboratory Scientists of Nigeria, Dr Ifeanyi Casmir, has said that most of the rapid diagnostic test kits used in the country are not validated ...